Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence

References

• Collaborators GBDMS. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269–285.
   PubMed Web of Science ®Google Scholar
• Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169–180.
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281.
   PubMed Web of Science ®Google Scholar
• Peelen E, Knippenberg S, Muris AH, et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev. 2011;10(12):733–743.
   PubMed Web of Science ®Google Scholar
• Bivona G, Agnello L, Ciaccio M. The immunological implication of the new vitamin D metabolism. Cent Eur J Immunol. 2018;43(3):331–334.
   PubMed Web of Science ®Google Scholar
• Bivona G, Gambino CM, Iacolino G, et al. Vitamin D and the nervous system. Neurol Res. 2019;41(9):827–835.
   PubMed Web of Science ®Google Scholar
• Scazzone C, Agnello L, Bivona G, et al. Vitamin D and Genetic Susceptibility to Multiple Sclerosis. Biochem Genet. 2021;59(1):1–30.
   PubMed Web of Science ®Google Scholar
• Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21–30.
   PubMed Web of Science ®Google Scholar
• Provvedini DM, Tsoukas CD, Deftos LJ, et al. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221(4616):1181–1183.
   PubMed Web of Science ®Google Scholar
• Prufer K, Veenstra TD, Jirikowski GF, et al. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat. 1999;16(2):135–145.
   PubMed Web of Science ®Google Scholar
• Smolders J, Damoiseaux J. Vitamin D as a T-cell modulator in multiple sclerosis. Vitam Horm 2011;86:401–428.
   Google Scholar
• Smolders J, Moen SM, Damoiseaux J, et al. Vitamin D in the healthy and inflamed central nervous system: access and function. J Neurol Sci. 2011;311(1–2):37–43.
   PubMed Web of Science ®Google Scholar
• Smolders J, Schuurman KG, van Strien ME, et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol. 2013;72(2):91–105.
   PubMed Web of Science ®Google Scholar
• Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009;132(Pt 5):1146–1160.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Epidemiologic contributions to multiple sclerosis: an overview. Neurology. 1980;30(7 Pt 2):61–79.
   PubMed Web of Science ®Google Scholar
• Kurtzke. Epidemiology in multiple sclerosis: a pilgrim’s progress. Brain. 2013;136(9):2904–2917.
   PubMed Web of Science ®Google Scholar
• Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60–65.
   PubMed Web of Science ®Google Scholar
• Nielsen NM, Munger KL, Koch-Henriksen N, et al. Neonatal vitamin D status and risk of multiple sclerosis: a population-based case-control study. Neurology. 2017;88(1):44–51.
   PubMed Web of Science ®Google Scholar
• Salzer J, Hallmans G, Nyström M, et al. Vitamin D as a protective factor in multiple sclerosis. Neurology. 2012;79(21):2140–2145.
   PubMed Web of Science ®Google Scholar
• Soilu- Hänninen M, Laaksonen M, Laitinen I, et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79(2):152–157.
   PubMed Web of Science ®Google Scholar
• van der Mei I, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ. 2003;327(7410):316.
   PubMed Web of Science ®Google Scholar
• Cortese M, Riise T, Bjornevik K, et al. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: the EnvIMS study. Mult Scler. 2015;21(14):1856–1864.
   PubMed Web of Science ®Google Scholar
• Munger RG, Sauberlich HE, Corcoran C, et al. Maternal vitamin B-6 and folate status and risk of oral cleft birth defects in the Philippines. Birth Defects Res A Clin Mol Teratol. 2004;70(7):464–471.
   PubMed Web of Science ®Google Scholar
• Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–2838.
   PubMed Web of Science ®Google Scholar
• Soilu- Hänninen M, Airas L, Mononen I, et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005;11(3):266–271.
   PubMed Web of Science ®Google Scholar
• Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68(2):193–203.
   PubMed Web of Science ®Google Scholar
• Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008;14(9):1220–1224.
   PubMed Web of Science ®Google Scholar
• van der Mei I, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254(5):581–590.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KC, Munger KL, Köchert K, et al. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015;72(12):1458–1465.
   PubMed Web of Science ®Google Scholar
• Muris A-H, Smolders J, Rolf L, et al. Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up. PLoS One. 2016;11(6):e0156122.
   PubMed Web of Science ®Google Scholar
• Becklund BR, Severson KS, Vang SV, et al. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci U S A. 2010;107(14):6418–6423.
   PubMed Web of Science ®Google Scholar
• Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat Rev Immunol. 2011;11(9):584–596.
   PubMed Web of Science ®Google Scholar
• Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–1859.
   PubMed Web of Science ®Google Scholar
• Stein MS, Liu Y, Gray OM, et al., A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 77(17): 1611–1618. 2011. .
   PubMed Web of Science ®Google Scholar
• Soilu-Hänninen M, Aivo J, B-m L, et al., A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 83(5): 565–571. 2012. .
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial Mult Scler Int. 2012; 2012: 452541.
   Google Scholar
• Kampman MT, Steffensen LH, Mellgren SI, et al. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler. 2012;18(8):1144–1151.
   PubMed Web of Science ®Google Scholar
• Golan D, Halhal B, Glass-Marmor L, et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol. 2013;13(1):60.
   PubMed Web of Science ®Google Scholar
• Achiron A, Givon U, Magalashvili D, et al., Effect of Alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Mult Scler. 21(6): 767–775. 2015. .
   PubMed Web of Science ®Google Scholar
• Sotirchos ES, Bhargava P, Eckstein C, et al., Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology. 86(4): 382–390. 2016. .
   PubMed Web of Science ®Google Scholar
• Hupperts R, Smolders J, Vieth R, et al., Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology. 93(20): e1906–e1916. 2019. .
   PubMed Web of Science ®Google Scholar
• Camu W, Lehert P, Pierrot-Deseilligny C, et al., Cholecalciferol in relapsing-remitting MS: a randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm. 6(5): e579. 2019. .
   PubMed Web of Science ®Google Scholar
• Dörr J, Bäcker-Koduah P, Wernecke K-D, et al. High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. Mult Scler J Exp Transl Clin. 2020;6(1):2055217320903474.
   Google Scholar
• Sormani MP, Signori A, Siri P, et al. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler. 2013;19(4):466–474.
   PubMed Web of Science ®Google Scholar
• Mosayebi G, Ghazavi A, Ghasami K, et al. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest. 2011;40(6):627–639.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Bonzano L, Roccatagliata L, Mancardi GL, et al. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? Mult Scler. 2009;15(9):1043–1047.
   PubMed Web of Science ®Google Scholar
• Pascual AM, Martinez-Bisbal MC, Bosca I, et al. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology. 2007;69(1):63–67.
   PubMed Web of Science ®Google Scholar
• Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(10):1082–1091.
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158–164.
   PubMed Web of Science ®Google Scholar
• Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5(5):256–266.
   PubMed Web of Science ®Google Scholar
• Cortese M, Munger KL, Martinez-Lapiscina EH, et al. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 2020;94(18):e1950–e1960.
   PubMed Web of Science ®Google Scholar
• Røsjø E, Lindstrøm JC, Holmøy T, et al. Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. Front Neurol. 2020;11:329.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21(8):1013–1024.
   PubMed Web of Science ®Google Scholar
• Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler. 2014;20(2):147–155.
   PubMed Web of Science ®Google Scholar
• Runia TF, Hop WC, de Rijke YB, et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012;79(3):261–266.
   PubMed Web of Science ®Google Scholar
• Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72(2):234–240.
   PubMed Web of Science ®Google Scholar
• Ostkamp P, Salmen A, Pignolet B, et al. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proc Natl Acad Sci U S A. 2021;118(1):e2018457118.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, White R, et al. Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurol. 2014;71(3):306–314.
   PubMed Web of Science ®Google Scholar
• James E, Dobson R, Kuhle J, et al. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler. 2013;19(12):1571–1579.
   PubMed Web of Science ®Google Scholar
• McLaughlin L, Clarke L, Khalilidehkordi E, et al. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol. 2018;265(12):2893–2905.
   PubMed Web of Science ®Google Scholar
• Derakhshandi H, Etemadifar M, Feizi A, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg. 2013;113(3):257–263.
   PubMed Web of Science ®Google Scholar
• Salari M, Janghorbani M, Etemadifar M, et al. Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: preliminary findings of a randomized, placebo-controlled trial. J Res Med Sci. 2015;20(4):372–378.
   PubMed Web of Science ®Google Scholar
• O’Connell K, Sulaimani J, Basdeo SA, et al. Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: a double-blind randomised controlled trial. Mult Scler J Exp Transl Clin. 2017;3(3):2055217317727296.
   Google Scholar
• Jagannath VA, Filippini G, Di Pietrantonj C, et al. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev. 2018;9(9):CD008422
   Google Scholar
• Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iran J Neurol. 2015;14(2):67–73.
   PubMed Web of Science ®Google Scholar
• Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, et al. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurol Res. 2016;38(10):888–892.
   PubMed Web of Science ®Google Scholar
• University of California SFMSET, Cree BAC, Gourraud P-A, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499–510.
   PubMed Web of Science ®Google Scholar
• Hempel S, Graham GD, Fu N, et al. A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis. Mult Scler. 2017;23(4):513–524.
   PubMed Web of Science ®Google Scholar
• Zheng C, He L, Liu L, et al. The efficacy of vitamin D in multiple sclerosis: a meta-analysis. Mult Scler Relat Disord. 2018;23:56–61.
   PubMed Web of Science ®Google Scholar
• Doosti-Irani A, Tamtaji OR, Mansournia MA, et al. The effects of vitamin D supplementation on expanded disability status scale in people with multiple sclerosis: a critical, systematic review and metaanalysis of randomized controlled trials. Clin Neurol Neurosurg. 2019;187:105564.
   Google Scholar
• Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 1996;47(6):1469–1476.
   PubMed Web of Science ®Google Scholar
• Smolders J, Torkildsen O, Camu W, et al. An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs. 2019 December;33(12):1187–1199.
   PubMed Web of Science ®Google Scholar
• Hart PH, Jones AP, Trend S, et al. A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: the PhoCIS study. Mult Scler J Exp Transl Clin. 2018;4(2):2055217318773112.
   Google Scholar
• Holowaychuk MK, Birkenheuer AJ, Li J, et al. Hypocalcemia and hypovitaminosis D in dogs with induced endotoxemia. J Vet Intern Med. 2012;26(2):244–251.
   PubMed Web of Science ®Google Scholar
• Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–58.
   PubMed Web of Science ®Google Scholar
• Pierrot-Deseilligny C, Rivaud-Pechoux S, Clerson P, et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord. 2012;5(4):187–198.
   PubMed Web of Science ®Google Scholar
• Häusler D, Weber MS. Vitamin D Supplementation in Central Nervous System Demyelinating Disease-Enough Is Enough. Int J Mol Sci. 2019;20(1):218.
   Web of Science ®Google Scholar
• Smolders J, Damoiseaux J, Hupperts R. Hypercalcaemia rather than high dose vitamin D3 supplements could exacerbate multiple sclerosis. Brain. 2019;142(12):e71.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lesaux J, Rice GP, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(9):1294–1296.
   PubMed Web of Science ®Google Scholar
• Kresevic DM, Denton JE, Burant CJ, et al. Racial Difference in Response to Vitamin D Supplementation. J Natl Med Assoc. 2015;107(2):18–24.
   PubMed Web of Science ®Google Scholar
• Muris AH, Rolf L, Broen K, et al. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. J Steroid Biochem Mol Biol. 2016;164:254–257.
   PubMed Web of Science ®Google Scholar
• Laursen JH, Sondergaard HB, Sorensen PS, et al. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Mult Scler Relat Disord. 2016;10:169–173.
   PubMed Web of Science ®Google Scholar
• Rotstein DL, Healy BC, Malik MT, et al. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e167.
   PubMed Web of Science ®Google Scholar
• Scott TF, Hackett CT, Dworek DC, et al. Low vitamin D level is associated with higher relapse rate in natalizumab treated MS patients. J Neurol Sci. 2013;330(1–2):27–31.
   PubMed Web of Science ®Google Scholar
• .International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2 et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476(7359):214–219.
   PubMed Web of Science ®Google Scholar
• Rhead B, Baarnhielm M, Gianfrancesco M, et al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet. 2016;2(5):e97.
   PubMed Web of Science ®Google Scholar
• Berlanga-Taylor AJ, Plant K, Dahl A, et al. Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial. EBioMedicine 2018;31:133–142.
   PubMed Web of Science ®Google Scholar
• Muris A-H, Smolders J, Rolf L, et al. Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study. J Neuroimmunol. 2016;300:47–56.
   PubMed Web of Science ®Google Scholar
• Damoiseaux J, Smolders J. The Engagement Between Vitamin D and the Immune System: is Consolidation by a Marriage to Be Expected? EBioMedicine 2018;31:9–10.
   PubMed Web of Science ®Google Scholar
• Boziki MK, Kesidou E, Theotokis P, et al. Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci. 2020;10(4):234.
   Web of Science ®Google Scholar
• Riccio P, Diet RR, Microbiota G. Vitamins D + A in Multiple Sclerosis. Neurotherapeutics. 2018;15(1):75–91.
   PubMed Web of Science ®Google Scholar